2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103262
    PSB069 78510-31-3 99.5%
    PSB069 bearing a p-chlorophenylamino residue is a potent, well-tolerated and nonselective NTPDases1, 2, 3 inhibitor(Ki=16~18 μM).
    PSB069
  • HY-103383
    (R)-DRF053 dihydrochloride 1241675-76-2 99.30%
    (R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and CDK5/p25 inhibitor with IC50s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model.
    (R)-DRF053 dihydrochloride
  • HY-110023
    Zimelidine dihydrochloride 60525-15-7 98.27%
    Zimelidine dihydrochloride is a potent and selective inhibitor of serotonin 5-HT uptake and SERT. Zimelidine dihydrochloride is an antidepressant.
    Zimelidine dihydrochloride
  • HY-110131
    A 85380 hydrochloride 174740-86-4
    A 85380 hydrochloride is a novel, high affinity neuronal nicotinic acetylcholine receptor (nAChR) agonist. A 85380 hydrochloride exhibits selectivity for the α4β2 nAChR subtypes. A 85380 hydrochloride has a broad-spectrum analgesic profile.
    A 85380 hydrochloride
  • HY-110289
    (R)-Citalopram oxalate 219861-53-7 99.52%
    (R)-Citalopram oxalate is an anticonvulsant, antidepressant and muscle relaxant. (R)-Citalopram oxalate is at least 20-fold weaker than S-citalopram (Escitalopram; HY-14258) as inhibitor of the 5-HT transporter (SERT). (R)-Citalopram oxalate functionally antagonises S-citalopram in vivo and in vitro. (R)-Citalopram oxalate has an effect on the association of Escitalopram with the high affinity primary site, and on its dissociation from the 5-HT transporter, via an allosteric mechanism.
    (R)-Citalopram oxalate
  • HY-112374
    NPAS3-IN-1 2207-44-5 98.29%
    NPAS3-IN-1 is a potent inhibitor of NPAS3-ARNT heterodimerization and regulates NPAS3 transcription by disrupting the heterodimerization of NPAS3 with ARNT at the cellular level.
    NPAS3-IN-1
  • HY-114508
    Dihydrochalcone 1083-30-3 99.87%
    Dihydrochalcone (3-Phenylpropiophenone) is a BBB-penatrable Aβ aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree.
    Dihydrochalcone
  • HY-119521
    Mexiletine 31828-71-4 99.92%
    Mexiletine is an orally effective antiarrhythmic agent which has also been found to be effective for myotonia and neuropathic pain. Mexiletine exerts its efficacy through blocking sodium channels (IC50 : 75±8 μM for tonic block, 23.6±2.8 μM for use-dependent block), therefore can be used for cardiovascular and neurological research.
    Mexiletine
  • HY-119594
    Melarsoprol 494-79-1 98.0%
    Melarsoprol, a melaminophenylarsine-type trivalent organic arsenical, is an important agent for African trypanosomiasis. Melarsoprol inhibits the growth of lymphoid leukemic cell by inducing apoptosis. Melarsoprol crosses the blood-brain barrier.
    Melarsoprol
  • HY-124344
    Avenanthramide C 116764-15-9 98.90%
    Avenanthramide C is an orally active avenanthramide that can be isolated from oat seeds. Avenanthramide C decreases the protein expression of cleaved caspase-3 and increases the expression of p-GSK3β(Ser9) and IL-10 levels. Avenanthramide C has the potential for the research of Alzheimer’s disease.
    Avenanthramide C
  • HY-125928
    AA43279 354812-16-1 ≥98.0%
    AA43279 is an in gamma-aminobutyric acid (GABA) fast-firing interneurons located activator for Nav1.1 channel (SCN1A) with an EC50 of 9.5 μM. AA43279 enhances specific neuronal firing activity in vitro, and exhibits anticonvulsant activity in rat MEST model.
    AA43279
  • HY-125972
    zr17-2 1263893-98-6 98.01%
    zr17-2 is a potent cannabinoid CB1 receptor modulator. zr17-2 reduces oxidative stress-induced retinal cell death.
    zr17-2
  • HY-130452
    NOS1-IN-1 357965-99-2
    NOS1-IN-1 is a selective and cell-permeable nNOS inhibitor with a Ki of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (Ki=39 μM) and iNOS (Ki=325 μM) , respectively. NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP).
    NOS1-IN-1
  • HY-13225B
    Rivanicline hemioxalate
    Rivanicline hemioxalate (RJR-2403 hemioxalate; (E)-Metanicotine hemioxalate) is a neuronal nicotinic receptor agonist, showing high selectivity for the α4β2 subtype (Ki=26 nM); > 1,000 fold selectivity than α7 receptors(Ki= 3.
    Rivanicline hemioxalate
  • HY-138978
    MF-095 2241021-89-4 98.7%
    MF-095 is a USP30 inhibitor. MF-095 promotes mitochondrial autophagy. MF-095 can be used in neurological disease-related research.
    MF-095
  • HY-14825A
    Tarafenacin D-tartrate 1159101-48-0 99.86%
    Tarafenacin D-tartrate (SVT-40776 D-tartrate) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.
    Tarafenacin D-tartrate
  • HY-150058
    Bocconoline 32906-88-0
    Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD).
    Bocconoline
  • HY-155403
    SCD1/5-IN-1 1241494-17-6 99.58%
    SCD1/5-IN-1 (Compound 10) is a SCD1/5 inhibitor. SCD1/5-IN-1 can be used for research of neurological disease.
    SCD1/5-IN-1
  • HY-156955
    SUCNR1-IN-2 2988733-54-4 99.74%
    SUCNR1-IN-2 (Statement 35) is a succinate/succinate receptor 1 inhibitor for the study of neurodegenerative diseases such as neuroinflammation.
    SUCNR1-IN-2
  • HY-157700
    Hexadecenyl-2-hydroxy-sn-glycero-3-PC 97802-53-4 99.40%
    Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) is a phosphatidylcholine. Hexadecenyl-2-hydroxy-sn-glycero-3-PC prolongs the lag-phase of α-syn aggregation, and can be used in Parkinson’s disease research.
    Hexadecenyl-2-hydroxy-sn-glycero-3-PC
Cat. No. Product Name / Synonyms Application Reactivity